Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BS HH 002.SA in AML and MDS
NCT04743115Phase 1Unknown
- Sponsor
- Shanghai Bensen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of BS-002 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Shanghai Bensen Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 28 days, Safety and Tolerability of BS HH 002.SA at 12 months and 1 more. Status: unknown.
02
Drugs
BS-002
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04743115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743115.